SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis

Current Opinion in Investigational Drugs

Volumn 10, Issue 9, 2009, Pages 988-996

  Oestreich, J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; SCH 530348; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; ATHEROSCLEROSIS; ATHEROTHROMBOSIS; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CELL HYPERPLASIA; CELL VACUOLE; CLINICAL TRIAL; CONVULSION; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; FATIGUE; FOOD DRUG INTERACTION; FOOD INTAKE; HEADACHE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; KUPFFER CELL; LIPIDOSIS; LIVER MICROSOME; LYMPH NODE; LYMPHOID CELL; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONKEY; MUSCLE ATROPHY; NAUSEA; NECROSIS; NONHUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PROTHROMBIN TIME; RETINA CELL; REVIEW; RISK ASSESSMENT; SERTOLI CELL; SKELETAL MUSCLE; STROKE; SWELLING; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ABSORPTION; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; LACTONES; MOLECULAR STRUCTURE; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, PAR-1; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS;

EID: 69549133824     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. 335120 Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Ahn HS, Arik L, Boykow G, Burnett DA, Caplen MA, Czarniecki M, Domalski MS, Foster C, Manna M, Stamford AW, Wu Y BIOORG MED CHEM LETT 1999 9 14 2073-2077
2. 403146 Discovery of potent, non-peptide thrombin receptor antagonists. Chackalamannil S, Costa R, Xia Y, Clasby M, Greenlee W, Doller D, Eagren K, Tsai H, Asberom T, Lin Y, Czariecki M et al ACS 2001 221 Abs MEDI-342
3. 425949 Potent, low molecular weight thrombin receptor antagonists. Chackalamannil S, Doller D, Eagen K, Czarniecki M, Ahn HS, Foster CJ, Boykow G BIOORG MED CHEM LETT 2001 11 21 2851-2853
4. 437882 Protease activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW PROC NATL ACAD SCI USA 1999 96 20 11189-11193
5. 587669 Design and synthesis of thrombin receptor (PAR-1) antagonists - Alfred Burger Award Address. Greenlee WJ ACS 2005 229 MEDI 18
6. 633128 Pharmacodynamics and pharmacokinetics of a novel protease-activated receptor (PAR-1) antagonist SCH 530348. Kosoglou T, Reyderman L, Fales RR, Yang B, Keller R, Shah A, Maxwell SE, Veltri EP, Cutler DL CIRCULATION 2005 112 suppl 17 Abs 245
7. 662596 FDA grants Fast Track designation to Schering-Plough for its thrombin receptor antagonist SCH 530348. Schering-Plough Corp PRESS RELEASE 2006 April 19
8. 758279 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK N ENGL J MED 2001 345 7 494-502
9. 785446 Schering-Plough announces initiation of two phase III clinical trials for novel selective antiplatelet therapy (TRA-SCH 530348). Schering-Plough Corp PRESS RELEASE 2007 April 18
10. 800459 Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ JAMA-J AM MED ASSOC 2002 288 19 2411-2420
11. 842433 Schering-Plough reports financial results for third quarter of 2007. Schering-Plough Corp PRESS RELEASE 2007 October 22
12. 842624 NCT00526474: Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with atherosclerosis (TRA 2° P - TIMI 50) (Study P04737) Schering-Plough Corp CLINICALTRIALS.GOV 2007
13. 850762 Thrombin receptor antagonist (TRA; SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics. Jennings LK, Earhart A, Becker RC, Reyderman L, Veltri E, Harrington RA CIRCULATION 2007 116 Suppl 16 Abs 3010
14. 859496 Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Wallentin L, Varenhorst C, James S, Erlinge D, Braun O, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A EUR HEART J 2008 29 1 21-30
15. 914215 SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Chintala M, Vemulapalli S, Kurowski S, Sabin C, Reynolds D, Prevete K, Friedrichs G ARTERIOSCLER THROMB VASC BIOL 2008 28 6 Abs P579
16. 923429 Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S et al J MED CHEM 2008 51 11 3061-3064 • Describes the discovery and optimization of himbacine-derived thrombin receptor antagonists and includes several pharmacokinetic and pharmacodynamic data from preclinical studies and clinical trials.
17. 957538 Pharmacologic profile of SCH 530348, a novel oral antiplatelet agent selective for the protease-activated receptor-1 (PAR-1). Chintala M, Ahn HS, Foster C, Agans J, Boykow G AM HEART ASSOC SCIENTIFIC SESSIONS 2008 118 18 Abs 1710
18. 966150 Schering-Plough highlights R&D pipeline progress, innovation and breadth of research projects. Schering-Plough Corp PRESS RELEASE 2008 November 24
19. 966270 Schering-Plough R&D update meeting (11/24/08). Schering- Plough Corp PRESS RELEASE 2008 November 24
20. 983503 Portola Pharmaceuticals enters worldwide license agreement for development and commercialization of novel antiplatelet drug elinogrel. Portola Pharmaceuticals Inc PRESS RELEASE 2009 February 12
21. 987486 Design and synthesis of thrombin receptor antagonists. Greenlee WJ, Chackalamannil S, Wang Y, Xia Y, Clasby M, Eagen K, Tsai H, Gao X, Boykow G, Chintala M AM CHEM SOC NATL MEET EXPOSITION 2009 237 Abs MEDI-131
22. 991379 Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study. Schering-Plough Corp PRESS RELEASE 2009 March 12
23. 991548 Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei JL, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW et al for the TRA-PCI Investigators LANCET 2009 373 9667 919-928 •• Describes a phase II clinical trial in patients with acute coronary syndromes scheduled to undergo non-urgent PCI. A dose-dependent effect of SCH-530348 on the occurrence of death or myocardial infarction and bleeding risk was reported at three separate loading and maintenance doses. The promising results from this study prompted further development of the drug in phase III testing.
24. 1000521 Trap-induced platelet aggregation following single and multiple rising oral doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers. Kosoglou T, Reyderman L, Tiessen R, Fales RR, Cutler DL, Keller R, Yang B, Van Lier JJ, Wadham A, Van Vliet AA CLIN PHARMACOL THER 2009 85 Suppl 1 Abs PI-40
25. 1000522 Lack of ethnic differences in the pharmacodynamics (pd) and pharmacokinetics (pk) of SCH 530348, a novel oral antiplatelet agent, in japanese and caucasian subjects. Reyderman L, Kosoglou T, Kasserra C, Young S, Pei J, Schiller J, Lin H, Cutler DL CLIN PHARMACOL THER 2009 85 Suppl 1 Abs PI-41
26. 1000523 The effect of food and antacid on pharmacokinetics (PK) of SCH 530348 in healthy subjects. Reyderman L, Kosoglou T, Tseng J, Xuan F, Schiller J, Cutler DL, Kim K CLIN PHARMACOL THER 2009 85 Suppl 1 Abs PI-42
27. 1000524 Basic and translational research on proteinase-activated receptors: Antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. Chintala M, Shimizu K, Ogawa M, Yamaguchi H, Doi M, Jensen P J PHARMACOL SCI 2008 108 4 433-438 • Highlights the unique pharmacology, lead compound optimization and preclinical and clinical development of SCH-530348.
28. 1000650 Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. Konorza TFM HERZ 2007 32 4 339
29. 1008341 Astrazeneca announces top line results from pivotal phase III study for Brilinta. Astrazeneca plc PRESS RELEASE 2009 May 11
30. 1009117 The Medicines Company discontinues phase 3 CHAMPION clinical trial program of cangrelor. The Medicines Company PRESS RELEASE 2009 May 13
31. 1022099 Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Kosoglou T, Reyderman L, Kasserra C, Young S, Pei J, Maxwell SE, Schiller J, Cutler DL CLIN PHARMACOL THER 2008 83 Suppl 1 Abs PII-42
32. 1022100 A phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke. Shinohara Y, Goto S, Shimizu K, Jensen P EUR STROKE CONF 2008 3 Suppl 1 Abs 139
33. 1022101 Phase II trial of the novel antiplatelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes (NSTE ACS). EUR HEART J 2008 29 Suppl 829 Abs P4767
34. 1024352 The top 10 causes of death. World Health Organization COMPANY PRESENTATION 2009 June 14
35. 1024353 Heart disease and stroke statistics 2009 update at-a-glance. American Heart Association COMPANY PRESENTATION 2009 June 14
36. 1024354 Cardiovascular disease: Prevention and control. World Health Organization COMPANY PRESENTATION 2009 June 14
37. 1024544 The primary and secondary prevention of coronary artery disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA CHEST 2008 133 Suppl 6 776S-814S
38. 1024707 Platelet activation and atherothrombosis. Davi G, Patrono C N ENGL J MED 2007 357 24 2482-2494
39. 1024710 Protease-activated receptors in cardiovascular diseases. Leger AJ, Covic L, Kuliopulos A CIRCULATION 2006 114 10 1070-1077
40. 1024711 Protease-activated receptors in hemostasis, thrombosis and vascular biology. Coughlin SR J THROMB HAEMOST 2005 3 8 1800-1814
41. 1024714 Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S CIRCULATION 2006 114 8 774-782
42. 1024715 Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA AM J CARDIOL 2005 96 9 1200-1206
43. 1024716 Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring. Xia Y, Chackalamannil S, Clasby M, Doller D, Eagen K, Greenlee WJ, Tsai H, Agans-Fantuzzi J, Ahn HS, Boykow GC, Hsieh Y et al BIOORG MED CHEM LETT 2007 17 16 4509-4513
44. 1024717 Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists. Chelliah MV, Chackalamannil S, Xia Y, Eagen K, Clasby MC, Gao X, Greenlee W, Ahn HS, Agans-Fantuzzi J, Boykow G, Hsieh Y et al J MED CHEM 2007 50 21 5147-5160
45. 1024718 Platelet function analysis: At the edge of meaning. Oestreich JH, Smyth SS, Campbell CL THROMB HAEMOST 2009 101 2 217-219
46. 1024720 Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) trial. Von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A CIRCULATION 2005 112 19 2946-2950
47. 1024721 Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP BLOOD 2003 101 10 3908-3914
48. 1024722 Variability in platelet responsiveness to clopidogrel among 544 individuals. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ J AM COLL CARDIOL 2005 45 2 246-251
49. 1024723 Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC AM J CARDIOL 2004 93 4 456-458
50. 1024808 Clopidogrel is associated with better in-hospital and 30- day outcomes than ticlopidine after coronary stenting. L'Allier PL, Aronow HD, Cura FA, Bhatt DL, Albirini A, Schneider JP, Topol EJ, Ellis SG CAN J CARDIOL 2003 19 9 1041-1046
51. 1024828 Metabolism-based identification of a potent thrombin receptor antagonist. Clasby MC, Chackalamannil S, Czarniecki M, Doller D, Eagen K, Greenlee W, Kao G, Lin Y, Tsai H, Xia Y, Ahn HS et al J MED CHEM 2007 50 1 129-138
52. 1024831 Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. Chackalamannil S, Xia Y, Greenlee WJ, Clasby M, Doller D, Tsai H, Asberom T, Czarniecki M, Ahn HS, Boykow G, Foster C et al J MED CHEM 2005 48 19 5884-5887
53. 1024853 Daiichi Sankyo and Lilly receive U.S. FDA approval for Effient. Eli Lilly & Co PRESS RELEASE 2009 July 10
54. 1025061 The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial: Study design and rationale. Tricoci P AM J HEMATOL 2009 In press •• Document prepared by the TRACER Executive and Steering Committees provides insight into the factors influencing the phase III study design and lists details regarding the TRACER trial unobtainable from other sources.
55. 1026945 A phase II safety study of novel antiplatelet agent, SCH 530348, in japanese patients with prior ischemic stroke. Shinohara Y, Goto S, Shimizu K, Jensen P INT J STROKE 2008 3 suppl 1 Abs PO01-193
56. 1027515 Himbacine analogs as muscarinic receptor antagonistseffects of tether and heterocyclic variations. Chackalamannil S, Doller D, McQuade R, Ruperto V BIOORG MED CHEM LETT 2004 14 15 3967-3970
57. 1029822 A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by vasp-phosphorylation and light transmission aggregometry. Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ THROMB HAEMOST 2008 99 1 215-222
58. 1031368 Effient is now available in pharmacies. Eli Lilly & Co PRESS RELEASE 2009 August 05